All Clinical Trials:
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects > 1 and < 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Clinical Trial Protocol # JNJ-54767414 | Adolescents and Young Adults, Leukemia/Lymphom, Recurrent/Refractory Cancer | Contact (714) 509-8646
TINI, Total Therapy For Infants with Acute Lymphoblastic Leukemia (ALL) I
Clinical Trial Protocol # TINI | Leukemia | Contact (714) 509-8646
ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Clinical Trial Protocol # ADVL1513 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
AHOD1721/BMS CA209744 – Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after
Clinical Trial Protocol # AHOD1721 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS
Clinical Trial Protocol # ADVL1711 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Clinical Trial Protocol # ADVL1614 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Oncology Clinical Trial: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant or Intolerant to Imatinib
Clinical Trial Protocol # 90325 | Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer, oncology | Contact (714) 509-8646
Oncology Clinical Trial: Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Clinical Trial | Supportive Care | Contact (714) 509-8646
Oncology Clinical Trial: Treatment for Advanced B-Cell Lymphoma
Clinical Trial | Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer | Contact (714) 509-8646
Oncology Clinical Trial: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Clinical Trial Protocol # ADVL1312 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Oncology Clinical Trial: Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Clinical Trial Protocol # ADVL1522 | Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
